These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

896 related articles for article (PubMed ID: 32941929)

  • 41. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
    Suzuki K; Iwata A; Iwatsubo T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tau-targeting therapies for Alzheimer disease: current status and future directions.
    Congdon EE; Ji C; Tetlow AM; Jiang Y; Sigurdsson EM
    Nat Rev Neurol; 2023 Dec; 19(12):715-736. PubMed ID: 37875627
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New treatment strategies for Alzheimer's disease: is there a hope?
    Aprahamian I; Stella F; Forlenza OV
    Indian J Med Res; 2013 Oct; 138(4):449-60. PubMed ID: 24434253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Distinct relationships of amyloid-beta and tau deposition to cerebral glucose metabolic networks in Alzheimer's disease.
    Sun X; Nie B; Zhao S; Ai L; Chen Q; Zhang T; Pan T; Wang L; Yin X; Zhang W; Shan B; Liu H; Liang S; Wang G
    Neurosci Lett; 2020 Jan; 717():134699. PubMed ID: 31874218
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current and emerging drug treatment options for Alzheimer's disease: a systematic review.
    Herrmann N; Chau SA; Kircanski I; Lanctôt KL
    Drugs; 2011 Oct; 71(15):2031-65. PubMed ID: 21985169
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors.
    Kuo YC; Rajesh R
    Expert Rev Neurother; 2019 Jul; 19(7):623-652. PubMed ID: 31109210
    [No Abstract]   [Full Text] [Related]  

  • 48. Update on Alzheimer's Disease Therapy and Prevention Strategies.
    Graham WV; Bonito-Oliva A; Sakmar TP
    Annu Rev Med; 2017 Jan; 68():413-430. PubMed ID: 28099083
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current Strategies and Novel Drug Approaches for Alzheimer Disease.
    Ghai R; Nagarajan K; Arora M; Grover P; Ali N; Kapoor G
    CNS Neurol Disord Drug Targets; 2020; 19(9):676-690. PubMed ID: 32679025
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.
    Shah TM; Gupta SM; Chatterjee P; Campbell M; Martins RN
    Mol Psychiatry; 2017 Mar; 22(3):353-363. PubMed ID: 28093567
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease.
    Park JC; Han SH; Yi D; Byun MS; Lee JH; Jang S; Ko K; Jeon SY; Lee YS; Kim YK; Lee DY; Mook-Jung I
    Brain; 2019 Mar; 142(3):771-786. PubMed ID: 30668647
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Molecular principles of tau-induced toxicity: new experimental therapy strategies for treatment of Alzheimer's disease].
    Schneider A; Falkai P; Papassotiropoulos A
    Nervenarzt; 2010 Nov; 81(11):1289-90, 1292, 1294, passim. PubMed ID: 20842339
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.
    Fisher A
    Neurotherapeutics; 2008 Jul; 5(3):433-42. PubMed ID: 18625455
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer's Disease.
    Leisher S; Bohorquez A; Gay M; Garcia V; Jones R; Baldaranov D; Rafii MS
    CNS Drugs; 2023 Aug; 37(8):671-677. PubMed ID: 37470978
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease.
    Uddin MS; Kabir MT; Niaz K; Jeandet P; Clément C; Mathew B; Rauf A; Rengasamy KRR; Sobarzo-Sánchez E; Ashraf GM; Aleya L
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32168835
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.
    Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies.
    Zetterberg H; Bendlin BB
    Mol Psychiatry; 2021 Jan; 26(1):296-308. PubMed ID: 32251378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alzheimer's disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs.
    Monteiro AR; Barbosa DJ; Remião F; Silva R
    Biochem Pharmacol; 2023 May; 211():115522. PubMed ID: 36996971
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.
    Golde TE
    J Neurochem; 2016 Oct; 139 Suppl 2(Suppl 2):224-236. PubMed ID: 27145445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.